Patents by Inventor Chufang Li

Chufang Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3CLPRO-TARGETING PHILLYRIN, DERIVATIVE THEREOF, AND USE THEREOF AGAINST NOVEL CORONAVIRUS
    Publication number: 20230101803
    Abstract: The present invention provides a use of a phillyrin/phillygenin composition which targets and inhibits 3CLpro protein of COVID-19 virus, in preparation of an anti-coronavirus drug or a drug for treating a disease caused by the coronavirus, wherein the coronavirus is COVID-19 virus, and the disease caused by the coronavirus is COVID-19.
    Type: Application
    Filed: February 9, 2021
    Publication date: March 30, 2023
    Inventors: Zifeng YANG, Li FU, Ge JIANG, Nanshan ZHONG, Wei YANG, Qinhai MA, Min HUI, Chufang LI, Shuo WANG, Weiyi PAN, Qi LU, Aiai SONG, Jirui HOU, Runfeng LI, Mingming LU, Yingping WANG, Yang LIU, Guoyou LIU, Wenfei FU, Xue FENG, Qingfeng ZHOU, Xiaofeng YI, Rongxin LIN, Yu ZHANG
  • Human Type 14 Replication Defective Adenovirus Vector and Preparation Method for Same and Applications Thereof
    Publication number: 20190388536
    Abstract: The present invention provides a human type 14 replication defective adenovirus vector, and a preparation method for the same, the method comprising: constructing an Ad14 genome into a plasmid, with knocking out E3 and E1 genes of the Ad14 genome, and replacing open reading frames 2, 3, 4, 6, and 6/7 of an E4 gene of the Ad14 genome with corresponding reading frames of an Ad5 genome. The human type 14 replication defective adenovirus vector according to the present invention is potentially applicable in the research and development of a vaccine and a drug against human type 14 adenovirus infection, applicable as a gene vector in the research and development of other pathogen vaccines, and applicable in a biological report and trace system, etc.
    Type: Application
    Filed: September 2, 2019
    Publication date: December 26, 2019
    Inventors: Ling Chen, Liqiang Feng, Chufang Li, Xikui Sun
  • Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
    Patent number: 8785442
    Abstract: The present invention relates to a compound as antagonist of LPA receptor, and a pharmaceutical composition comprising the same. The present invention also relates to the use of the compound and the composition, and a method of using the compound to treat, prevent or diagnose diseases, disorders or conditions associated with one or more of the LPA receptors.
    Type: Grant
    Filed: January 30, 2011
    Date of Patent: July 22, 2014
    Assignee: Curegenix, Inc.
    Inventors: Songzhu An, Chufang Li, Guisheng Zhou, Chen Huang
  • COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF
    Publication number: 20140031353
    Abstract: The present invention relates to a compound as antagonist of LPA receptor, and a pharmaceutical composition comprising the same. The present invention also relates to the use of the compound and the composition, and a method of using the compound to treat, prevent or diagnose diseases, disorders or conditions associated with one or more of the LPA receptors.
    Type: Application
    Filed: January 30, 2011
    Publication date: January 30, 2014
    Applicant: CUREGENIX, INC.
    Inventors: Songzhu An, Chufang Li, Guisheng Zhou, Chen Huang